Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Chaffanet, M"" wg kryterium: Wszystkie pola


Tytuł :
SLX4 interacts with RTEL1 to prevent transcription-mediated DNA replication perturbations
Autorzy :
Takedachi, A.Aff1, Aff2, Aff10
Despras, E.
Scaglione, S.
Guérois, R.
Guervilly, J. H.
Blin, M.
Audebert, S.
Camoin, L.
Hasanova, Z.Aff1, Aff11
Schertzer, M.Aff5, Aff6
Guille, A.
Churikov, D.
Callebaut, I.
Naim, V.
Chaffanet, M.
Borg, J. P.
Bertucci, F.
Revy, P.
Birnbaum, D.
Londoño-Vallejo, A.Aff5, Aff6
Kannouche, P. L.
Gaillard, P. H. L.
Pokaż więcej
Źródło :
Nature Structural & Molecular Biology. 27(5):438-449
Czasopismo naukowe
Tytuł :
A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study
Autorzy :
Collignon, A.
Hospital, M. A.
Montersino, C.
Courtier, F.
Charbonnier, A.
Saillard, C.
D’Incan, E.
Mohty, B.
Guille, A.
Adelaïde, J.
Carbuccia, N.
Garnier, S.
Mozziconacci, M. J.
Zemmour, C.
Pakradouni, J.
Restouin, A.
Castellano, R.
Chaffanet, M.
Birnbaum, D.
Collette, Y.
Vey, N.
Pokaż więcej
Źródło :
Blood Cancer Journal. 10(6)
Czasopismo naukowe
Tytuł :
Author Correction: SLX4 interacts with RTEL1 to prevent transcription-mediated DNA replication perturbations
Autorzy :
Takedachi, A.Aff1, Aff2, Aff10
Despras, E.
Scaglione, S.
Guérois, R.
Guervilly, J. H.
Blin, M.
Audebert, S.
Camoin, L.
Hasanova, Z.Aff1, Aff11
Schertzer, M.Aff5, Aff6
Guille, A.
Churikov, D.
Callebaut, I.
Naim, V.
Chaffanet, M.
Borg, J. P.
Bertucci, F.
Revy, P.
Birnbaum, D.
Londoño-Vallejo, A.Aff5, Aff6
Kannouche, P. L.
Gaillard, P. H. L.
Pokaż więcej
Źródło :
Nature Structural & Molecular Biology. 27(6):603-603
Czasopismo naukowe
Tytuł :
Publisher Correction: SLX4 interacts with RTEL1 to prevent transcription-mediated DNA replication perturbations
Autorzy :
Takedachi, A.Aff1, Aff2, Aff10
Despras, E.
Scaglione, S.
Guérois, R.
Guervilly, J. H.
Blin, M.
Audebert, S.
Camoin, L.
Hasanova, Z.Aff1, Aff11
Schertzer, M.Aff5, Aff6
Guille, A.
Churikov, D.
Callebaut, I.
Naim, V.
Chaffanet, M.
Borg, J. P.
Bertucci, F.
Revy, P.
Birnbaum, D.
Londoño-Vallejo, A.Aff5, Aff6
Kannouche, P. L.
Gaillard, P. H. L.
Pokaż więcej
Źródło :
Nature Structural & Molecular Biology. 27(6):604-604
Czasopismo naukowe
Tytuł :
Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity.
Autorzy :
Cherif C; Predictive Oncology Laboratory, Centre de Recherche en Cancérologie de Marseille, Inserm UMR 1068, CNRS UMR 7258, Institut Paoli-Calmettes, Aix-Marseille University, 27 Bd. Leï Roure, F-13009 Marseille, France.; Laboratory of Biochemistry and Molecular Biology, Science University of Tunis, 2092, El Manar, Tunis, Tunisia.
Nguyen DT; Predictive Oncology Laboratory, Centre de Recherche en Cancérologie de Marseille, Inserm UMR 1068, CNRS UMR 7258, Institut Paoli-Calmettes, Aix-Marseille University, 27 Bd. Leï Roure, F-13009 Marseille, France.
Paris C; Predictive Oncology Laboratory, Centre de Recherche en Cancérologie de Marseille, Inserm UMR 1068, CNRS UMR 7258, Institut Paoli-Calmettes, Aix-Marseille University, 27 Bd. Leï Roure, F-13009 Marseille, France.
Le TK; Predictive Oncology Laboratory, Centre de Recherche en Cancérologie de Marseille, Inserm UMR 1068, CNRS UMR 7258, Institut Paoli-Calmettes, Aix-Marseille University, 27 Bd. Leï Roure, F-13009 Marseille, France.
Sefiane T; Predictive Oncology Laboratory, Centre de Recherche en Cancérologie de Marseille, Inserm UMR 1068, CNRS UMR 7258, Institut Paoli-Calmettes, Aix-Marseille University, 27 Bd. Leï Roure, F-13009 Marseille, France.
Carbuccia N; Predictive Oncology Laboratory, Centre de Recherche en Cancérologie de Marseille, Inserm UMR 1068, CNRS UMR 7258, Institut Paoli-Calmettes, Aix-Marseille University, 27 Bd. Leï Roure, F-13009 Marseille, France.
Finetti P; Predictive Oncology Laboratory, Centre de Recherche en Cancérologie de Marseille, Inserm UMR 1068, CNRS UMR 7258, Institut Paoli-Calmettes, Aix-Marseille University, 27 Bd. Leï Roure, F-13009 Marseille, France.
Chaffanet M; Predictive Oncology Laboratory, Centre de Recherche en Cancérologie de Marseille, Inserm UMR 1068, CNRS UMR 7258, Institut Paoli-Calmettes, Aix-Marseille University, 27 Bd. Leï Roure, F-13009 Marseille, France.
Kaoutari AE; Predictive Oncology Laboratory, Centre de Recherche en Cancérologie de Marseille, Inserm UMR 1068, CNRS UMR 7258, Institut Paoli-Calmettes, Aix-Marseille University, 27 Bd. Leï Roure, F-13009 Marseille, France.
Vernerey J; Predictive Oncology Laboratory, Centre de Recherche en Cancérologie de Marseille, Inserm UMR 1068, CNRS UMR 7258, Institut Paoli-Calmettes, Aix-Marseille University, 27 Bd. Leï Roure, F-13009 Marseille, France.
Fazli L; The Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada.
Gleave M; The Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada.
Manai M; Laboratory of Biochemistry and Molecular Biology, Science University of Tunis, 2092, El Manar, Tunis, Tunisia.
Barthélémy P; ARNA Laboratory, INSERM U1212, CNRS UMR 5320, University of Bordeaux, F-33076 Bordeaux, France.
Birnbaum D; Predictive Oncology Laboratory, Centre de Recherche en Cancérologie de Marseille, Inserm UMR 1068, CNRS UMR 7258, Institut Paoli-Calmettes, Aix-Marseille University, 27 Bd. Leï Roure, F-13009 Marseille, France.
Bertucci F; Predictive Oncology Laboratory, Centre de Recherche en Cancérologie de Marseille, Inserm UMR 1068, CNRS UMR 7258, Institut Paoli-Calmettes, Aix-Marseille University, 27 Bd. Leï Roure, F-13009 Marseille, France.
Taïeb D; Predictive Oncology Laboratory, Centre de Recherche en Cancérologie de Marseille, Inserm UMR 1068, CNRS UMR 7258, Institut Paoli-Calmettes, Aix-Marseille University, 27 Bd. Leï Roure, F-13009 Marseille, France.; Biophysics and Nuclear Medicine Department, La Timone University Hospital, European Center for Research in Medical Imaging, Aix-Marseille University, F-13005 Marseille, France.
Rocchi P; Predictive Oncology Laboratory, Centre de Recherche en Cancérologie de Marseille, Inserm UMR 1068, CNRS UMR 7258, Institut Paoli-Calmettes, Aix-Marseille University, 27 Bd. Leï Roure, F-13009 Marseille, France. .
Pokaż więcej
Źródło :
Oncogene [Oncogene] 2022 Jan; Vol. 41 (1), pp. 125-137. Date of Electronic Publication: 2021 Oct 28.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients.
Autorzy :
Vicier C; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France; Predictive Oncology Laboratory, CRCM, Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille Univ, Marseille, France.
Sfumato P; Department of Clinical Research and Innovation, Institut Paoli-Calmettes, Marseille, France.
Isambert N; Drug Development Department, Centre Georges François Leclerc, Dijon, France.
Dalenc F; Department of Medical Oncology, Institut Claudius Regaud, IUCT-Oncopole, CRCT, Inserm, Toulouse, France.
Robert M; Institut de Cancérologie de l'Ouest-René Gauducheau, Saint-Herblain, France.
Levy C; Centre François Baclesse, Department of Medical Oncology, Caen, France.
Rezai K; Department of Radio-Pharmacology, Institut Curie, St Cloud, France.
Provansal M; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.
Adélaïde J; Predictive Oncology Laboratory, CRCM, Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille Univ, Marseille, France.
Garnier S; Predictive Oncology Laboratory, CRCM, Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille Univ, Marseille, France.
Guille A; Predictive Oncology Laboratory, CRCM, Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille Univ, Marseille, France.
Carbuccia N; Predictive Oncology Laboratory, CRCM, Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille Univ, Marseille, France.
Popovici C; Department of Oncogenetics, Institut Paoli-Calmettes, Marseille, France.
Charafe-Jauffret E; Aix Marseille University, Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Biopathology Department, CRCM, Marseille, France.
Chaffanet M; Predictive Oncology Laboratory, CRCM, Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille Univ, Marseille, France.
Birnbaum D; Predictive Oncology Laboratory, CRCM, Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille Univ, Marseille, France.
Pakradouni J; Department of Clinical Research and Innovation, Institut Paoli-Calmettes, Marseille, France.
Bertucci F; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France; Predictive Oncology Laboratory, CRCM, Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille Univ, Marseille, France.
Boher JM; Department of Clinical Research and Innovation, Institut Paoli-Calmettes, Marseille, France; Aix Marseille University, INSERM, IRD, SESSTIM, Marseille, France.
Sabatier R; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France; Predictive Oncology Laboratory, CRCM, Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille Univ, Marseille, France.
Gonçalves A; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France; Predictive Oncology Laboratory, CRCM, Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille Univ, Marseille, France. Electronic address: .
Pokaż więcej
Źródło :
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2021 Dec; Vol. 159, pp. 205-214. Date of Electronic Publication: 2021 Nov 12.
Typ publikacji :
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Enzyme Inhibitors/*administration & dosage
Paclitaxel/*administration & dosage
Triple Negative Breast Neoplasms/*drug therapy
Adult ; Aged ; Female ; Humans ; Middle Aged ; Proto-Oncogene Proteins c-akt/antagonists & inhibitors ; Ribosomal Protein S6 Kinases, 70-kDa/antagonists & inhibitors
Czasopismo naukowe
Tytuł :
Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
Autorzy :
Bertucci F; Laboratory of Predictive Oncology, Department of Medical Oncology, Centre de Recherche en Cancérologie de Marseille (CRCM), Institut Paoli-Calmettes, INSERM UMR1068, CNRS UMR725, Aix-Marseille University, 232 Boulevard Sainte-Marguerite, 13009, Marseille, France. .; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France. .
Gonçalves A; Laboratory of Predictive Oncology, Department of Medical Oncology, Centre de Recherche en Cancérologie de Marseille (CRCM), Institut Paoli-Calmettes, INSERM UMR1068, CNRS UMR725, Aix-Marseille University, 232 Boulevard Sainte-Marguerite, 13009, Marseille, France.; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.
Guille A; Laboratory of Predictive Oncology, Department of Medical Oncology, Centre de Recherche en Cancérologie de Marseille (CRCM), Institut Paoli-Calmettes, INSERM UMR1068, CNRS UMR725, Aix-Marseille University, 232 Boulevard Sainte-Marguerite, 13009, Marseille, France.
Adelaïde J; Laboratory of Predictive Oncology, Department of Medical Oncology, Centre de Recherche en Cancérologie de Marseille (CRCM), Institut Paoli-Calmettes, INSERM UMR1068, CNRS UMR725, Aix-Marseille University, 232 Boulevard Sainte-Marguerite, 13009, Marseille, France.
Garnier S; Laboratory of Predictive Oncology, Department of Medical Oncology, Centre de Recherche en Cancérologie de Marseille (CRCM), Institut Paoli-Calmettes, INSERM UMR1068, CNRS UMR725, Aix-Marseille University, 232 Boulevard Sainte-Marguerite, 13009, Marseille, France.
Carbuccia N; Laboratory of Predictive Oncology, Department of Medical Oncology, Centre de Recherche en Cancérologie de Marseille (CRCM), Institut Paoli-Calmettes, INSERM UMR1068, CNRS UMR725, Aix-Marseille University, 232 Boulevard Sainte-Marguerite, 13009, Marseille, France.
Billon E; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.
Finetti P; Laboratory of Predictive Oncology, Department of Medical Oncology, Centre de Recherche en Cancérologie de Marseille (CRCM), Institut Paoli-Calmettes, INSERM UMR1068, CNRS UMR725, Aix-Marseille University, 232 Boulevard Sainte-Marguerite, 13009, Marseille, France.
Sfumato P; Biostatistics Unit, Institut Paoli-Calmettes, Marseille, France.
Monneur A; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.
Pécheux C; Department of Medical genetics, Hôpital Timone Enfants, AP-HM, Marseille, France.
Khran M; Department of Medical genetics, Hôpital Timone Enfants, AP-HM, Marseille, France.; Aix-Marseille University, Inserm, U1251-MMG, Marseille Medical Genetics, Marseille, France.
Brunelle S; Department of Imaging, Institut Paoli-Calmettes, Marseille, France.
Mescam L; Department of Biopathology, Institut Paoli-Calmettes, Marseille, France.
Thomassin-Piana J; Department of Biopathology, Institut Paoli-Calmettes, Marseille, France.
Poizat F; Department of Biopathology, Institut Paoli-Calmettes, Marseille, France.
Charafe-Jauffret E; Department of Biopathology, Institut Paoli-Calmettes, Marseille, France.
Turrini O; Department of Surgical Oncology, Institut Paoli-Calmettes, Marseille, France.
Lambaudie E; Department of Surgical Oncology, Institut Paoli-Calmettes, Marseille, France.
Provansal M; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.
Extra JM; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.
Madroszyk A; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.
Gilabert M; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.
Sabatier R; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.
Vicier C; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.
Mamessier E; Laboratory of Predictive Oncology, Department of Medical Oncology, Centre de Recherche en Cancérologie de Marseille (CRCM), Institut Paoli-Calmettes, INSERM UMR1068, CNRS UMR725, Aix-Marseille University, 232 Boulevard Sainte-Marguerite, 13009, Marseille, France.
Chabannon C; Biobank, Department of Hematology, Institut Paoli-Calmettes, Marseille, France.
Pakradouni J; Department of Clinical Research and Innovation, Institut Paoli-Calmettes, Marseille, France.
Viens P; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.
André F; Department of Medical Oncology, Gustave Roussy Cancer Campus, UMR981 Inserm, Villejuif, France.; Paris Sud University, Orsay, France.
Gravis G; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.
Popovici C; Department of Oncogenetics, Institut Paoli-Calmettes, Marseille, France.
Birnbaum D; Laboratory of Predictive Oncology, Department of Medical Oncology, Centre de Recherche en Cancérologie de Marseille (CRCM), Institut Paoli-Calmettes, INSERM UMR1068, CNRS UMR725, Aix-Marseille University, 232 Boulevard Sainte-Marguerite, 13009, Marseille, France.
Chaffanet M; Laboratory of Predictive Oncology, Department of Medical Oncology, Centre de Recherche en Cancérologie de Marseille (CRCM), Institut Paoli-Calmettes, INSERM UMR1068, CNRS UMR725, Aix-Marseille University, 232 Boulevard Sainte-Marguerite, 13009, Marseille, France.
Pokaż więcej
Źródło :
Genome medicine [Genome Med] 2021 May 18; Vol. 13 (1), pp. 87. Date of Electronic Publication: 2021 May 18.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
Czasopismo naukowe
Tytuł :
Case Report: Two Cases of Metastatic Pancreatoblastoma in Adults: Efficacy of Folfirinox and Implication of the Wnt/β-Catenin Pathway in Genomic Analysis.
Autorzy :
Raoul JL; Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Saint-Herblain, France.
Oziel-Taieb S; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.
Lecomte T; Department of Hepatogastroenterology, CHU Tours, Tours, France.
Adelaide J; Predictive Oncology Laboratory, Centre de Recherche en Cancérologie de Marseille, Marseille, France.
Guille A; Predictive Oncology Laboratory, Centre de Recherche en Cancérologie de Marseille, Marseille, France.
Chaffanet M; Predictive Oncology Laboratory, Centre de Recherche en Cancérologie de Marseille, Marseille, France.
Poizat F; Department of Pathology, Institut Paoli-Calmettes, Marseille, France.
Heymann MF; Department of Pathology, Institut de Cancérologie de l'Ouest, Saint-Herblain, France.
Barbier L; Department of Digestive Surgery, CHU Tours, Tours, France.
Bertucci F; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.; Predictive Oncology Laboratory, Centre de Recherche en Cancérologie de Marseille, Marseille, France.
Pokaż więcej
Źródło :
Frontiers in oncology [Front Oncol] 2021 Mar 16; Vol. 11, pp. 564506. Date of Electronic Publication: 2021 Mar 16 (Print Publication: 2021).
Typ publikacji :
Case Reports
Raport
Tytuł :
A major response to carboplatin in a metastatic triple-negative breast cancer patient with somatic mutation of BRCA1 and RAD51B: When chemotherapy meets precision medicine
Autorzy :
Seguin, L.
Chaffanet, M.
Sabatier, R.
Jose, A.
Garnier, S.
Carbuccia, N.
GUILLE, A.
Birnbaum, D.
Bertucci, F.
Goncalves, A.
Pokaż więcej
Temat :
[SDV]Life Sciences [q-bio]
Źródło :
Annals of Oncology, Oxford University Press (OUP), 2018, 29 (6), ⟨10.1093/annonc/mdy314.030⟩

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies